Elaine Eisen, CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS
Virtually all pharmaceutical manufacturers have robust policies to place needed medicines in the hands of those who cannot afford to pay for them.
Elaine Eisen
PRESIDENT | CORBETT WORLDWIDE HEALTHCARE COMMUNICATIONS
Ironically, pharma has many patient assistance programs already firmly in place (established well before the current economic downturn). There is probably no other industry in America that has as many established initiatives to assure continuity of care for the customer.
Virtually all pharmaceutical manufacturers have robust policies to place needed medicines in the hands of those who cannot afford to pay for them. Although this is certainly not an exhaustive list, what follows is merely a portion of the programs that pharma has sponsored to safeguard the health of patients: the AstraZeneca Prescription Savings Program, the Merck Patient Assistance Program, the Alcon U.S. Patient Assistance Program, the Pfizer Friends Program, the Bristol-Myers Squibb Patient Assistance Foundation, the Procter & Gamble Pharmaceuticals Patient Assistance Program, and the Sanofi-Aventis Patient Assistance Program. Perhaps pharma needs to "toot its own horn" a little more loudly and recognize that those of us who work in the pharmaceutical industry are dedicated to extending and enhancing human life.
Elaine Eisen
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
